AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31315670 — intervention group
Group type: COMPARATOR
Intervention: bilateral sham block (20 mL NaCl 0.9%)
Number of subjects: 80
Study 28322776 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mL/h of normal saline
Number of subjects: 274
Study 28322776 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mL/h of 5% dextrose in normal saline
Number of subjects: 274
Study 28322776 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mL/h of 2.5% dextrose in normal saline
Number of subjects: 274
Study 28322776 — intervention group
Group type: COMPARATOR
Intervention: Control group (250 mL/h of normal saline)
Number of subjects: 274
Study 28322776 — intervention group
Group type: COMPARATOR
Intervention: Control group (125 mL/h of 5% dextrose in normal saline)
Number of subjects: 274
Study 28322776 — intervention group
Group type: COMPARATOR
Intervention: Control group (250 mL/h of 2.5% dextrose in normal saline)
Number of subjects: 274
Study 28322776 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 274
Study 26016162 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant radiotherapy with Ir‐192
Number of subjects: 105
Study 26016162 — intervention group
Group type: COMPARATOR
Intervention: Radical prostatectomy followed by adjuvant remote radiotherapy
Number of subjects: 105
Study 24174945 — intervention group
Group type: EXPERIMENTAL
Intervention: Septal injection of 40 U of BTA (Dysport(®), Ipsen Ltd)
Number of subjects: 50
Study 24174945 — intervention group
Group type: COMPARATOR
Intervention: Turbinal injection of 40 U of BTA (Dysport(®), Ipsen Ltd)
Number of subjects: 50
Study 21696934 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol (FSC) 250/50 μg twice-daily
Number of subjects: 249
Study 21696934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study 19929596 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral bevacizumab injection at a concentration of 1.25 mg/0.05 mL
Number of subjects: 10
Study 19929596 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral bevacizumab injection
Number of subjects: 10
Study 18200772 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0
Study 18200772 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS
Number of subjects: 0
Study 18200772 — intervention group
Group type: COMPARATOR
Intervention: Co-amilozide (amiloride plus hydrochlorothiazide)
Number of subjects: 0
Study 15116815 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track rehabilitation with continuous epidural analgesia, enforced oral nutrition, mobilisation, planned early discharge
Number of subjects: 30
Study 15116815 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 30
Study 15116815 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track rehabilitation
Number of subjects: 30
Study 10757250 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 0.5 mg
Number of subjects: 20
Study 10757250 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 1 mg
Number of subjects: 20
Study 10757250 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg
Number of subjects: 20
Study 10757250 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg
Number of subjects: 20
Study 10757250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9380353 — intervention group
Group type: EXPERIMENTAL
Intervention: Apraclonidine 1%
Number of subjects: 12
Study 9380353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8404935 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase initiated 12-49 hours after onset of symptoms, followed by heparin for at least 5 days and warfarin and dipyridamole for at least 3 months
Number of subjects: 111
Study 8404935 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment without any of these drugs
Number of subjects: 111
Study 3950112 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% indomethacin cream
Number of subjects: 30
Study 3950112 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% meclofenamate cream
Number of subjects: 30
Study 3950112 — intervention group
Group type: COMPARATOR
Intervention: Vehicle therapy
Number of subjects: 30
Study 30374890 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil 12 ng/ml (Group 5)
Number of subjects: 198
Study 30374890 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including Group 1: 0 ng/ml, Group 2: 2 ng/ml, Group 3: 4 ng/ml, Group 4: 8 ng/ml, Group 5: 12 ng/ml)
Number of subjects: 198
Study 26762908 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer-generation drug-eluting stents (DES)
Number of subjects: 4217
Study 26762908 — intervention group
Group type: COMPARATOR
Intervention: Older-generation drug-eluting stents (DES)
Number of subjects: 4217
Study 26762908 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatinine clearance (CrCl) <45 ml/min
Number of subjects: 4217
Study 26762908 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatinine clearance (CrCl) 45 to 59 ml/min
Number of subjects: 4217
Study 26762908 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatinine clearance (CrCl) ≥60 ml/min
Number of subjects: 4217
Study 24332588 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone therapy on the study side
Number of subjects: 60
Study 24332588 — intervention group
Group type: COMPARATOR
Intervention: Sham ozone therapy on the control side
Number of subjects: 60
Study 24332588 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone therapy
Number of subjects: 60
Study 22616058 — intervention group
Group type: EXPERIMENTAL
Intervention: Materialise SimPlant
Number of subjects: 14
Study 22616058 — intervention group
Group type: EXPERIMENTAL
Intervention: Nobel Biocare
Number of subjects: 14
Study 22616058 — intervention group
Group type: COMPARATOR
Intervention: Bone-supported guides
Number of subjects: 14
Study 22616058 — intervention group
Group type: EXPERIMENTAL
Intervention: All provisionals
Number of subjects: 14
Study 20339731 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing + thought mapping + cognitive-behavioral group therapy
Number of subjects: 40
Study 20339731 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral group therapy
Number of subjects: 40
Study 18503905 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 201
Study 18503905 — intervention group
Group type: COMPARATOR
Intervention: Empathic Attention
Number of subjects: 201
Study 18503905 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 201
Study 15935383 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin (300 mg twice daily) and Azithromycin (500 mg every other day) for 6 months
Number of subjects: 8
Study 15935383 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 8
Study 12575975 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc‐99m sestamibi injected during last balloon inflation (acute MPI)
Number of subjects: 40
Study 12575975 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc‐99m sestamibi injected at 15 min following balloon deflation (delayed MPI)
Number of subjects: 40
Study 12575975 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc‐99m sestamibi injected at 1, 2, or 3 h (delayed MPI)
Number of subjects: 40
Study 12575975 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc‐99m sestamibi injected at 24 to 48 h (late MPI)
Number of subjects: 40
Study 10556995 — intervention group
Group type: EXPERIMENTAL
Intervention: Extruded blended flour (EF)
Number of subjects: 8
Study 10556995 — intervention group
Group type: COMPARATOR
Intervention: Non-extruded blended flour (NEF)
Number of subjects: 8
Study 8701885 — intervention group
Group type: EXPERIMENTAL
Intervention: Wiktor stent implantation
Number of subjects: 84
Study 8701885 — intervention group
Group type: COMPARATOR
Intervention: Conventional balloon angioplasty
Number of subjects: 84
Study 1895045 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intravenous metoprolol followed by oral treatment for 15 days
Number of subjects: 5778
Study 1895045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5778
Study 6340971 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaprozin 1200 mg once daily
Number of subjects: 20
Study 6340971 — intervention group
Group type: COMPARATOR
Intervention: Sulindac 200 mg twice daily
Number of subjects: 20
Study 30999762 — intervention group
Group type: EXPERIMENTAL
Intervention: Matching product attributes
Number of subjects: 20000
Study 29248173 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube shunt (350‐mm2 Baerveldt glaucoma implant)
Number of subjects: 0
Study 29248173 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy with mitomycin C (0.4 mg/ml for 2 minutes)
Number of subjects: 0
Study 26611525 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% NaCl+ambroxol
Number of subjects: 30
Study 26611525 — intervention group
Group type: COMPARATOR
Intervention: 0.45% NaCl
Number of subjects: 30
Study 25075828 — intervention group
Group type: EXPERIMENTAL
Intervention: Cases (CVTs who reported work-related bite injuries)
Number of subjects: 868
Study 25075828 — intervention group
Group type: COMPARATOR
Intervention: Controls (CVTs who did not report work-related bite injuries)
Number of subjects: 868
Study 21948120 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (EG, n=40)
Number of subjects: 83
Study 21948120 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG, n=43)
Number of subjects: 83
Study 18988860 — intervention group
Group type: EXPERIMENTAL
Intervention: History of moderate to severe childhood abuse
Number of subjects: 0
Study 17553394 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits
Number of subjects: 351
Study 17553394 — intervention group
Group type: COMPARATOR
Intervention: Day hospital visits
Number of subjects: 351
Study 15219654 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal betamethasone treatment (2 doses of 12 mg administered intramuscularly to the mother twelve hours apart)
Number of subjects: 18
Study 15219654 — intervention group
Group type: COMPARATOR
Intervention: No antenatal betamethasone treatment
Number of subjects: 18
Study 12234700 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 488
Study 12234700 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and VP-16 administered concurrently with radiotherapy (CRT)
Number of subjects: 488
Study 12234700 — intervention group
Group type: COMPARATOR
Intervention: Overall survival comparison between genders
Number of subjects: 488
Study 12234700 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-squamous histology tumors in women
Number of subjects: 488
Study 9664953 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA‐ME (cyclosporine microemulsion)
Number of subjects: 31
Study 9664953 — intervention group
Group type: COMPARATOR
Intervention: CsA (original formulation of cyclosporine)
Number of subjects: 31
Study 9664953 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA‐ME
Number of subjects: 31
Study 8583176 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical manipulation
Number of subjects: 0
Study 8583176 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 0
Study 2803892 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 12.5 mg i.v. and 37.5 mg i.m.
Number of subjects: 48
Study 2803892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 31722150 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA
Number of subjects: 440
Study 31722150 — intervention group
Group type: COMPARATOR
Intervention: ACAM2000
Number of subjects: 440
Study 27863315 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2mA/20min/day for 5 days)
Number of subjects: 17
Study 27863315 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 17
Study 27863315 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 17
Study 26666523 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing into the snow with a one-liter air pocket (AP)
Number of subjects: 10
Study 26666523 — intervention group
Group type: COMPARATOR
Intervention: Breathing into the snow with no air pocket (NP)
Number of subjects: 10
Study 23073706 — intervention group
Group type: EXPERIMENTAL
Intervention: MIS anterolateral approach
Number of subjects: 156
Study 23073706 — intervention group
Group type: COMPARATOR
Intervention: Surgeon's preferred approach (direct lateral or posterolateral)
Number of subjects: 156
Study 23073706 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 156
Study 23073706 — intervention group
Group type: EXPERIMENTAL
Intervention: MIS anterolateral group
Number of subjects: 156
Study 21640214 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Bearing Exercises Program (WBEP)
Number of subjects: 45
Study 21640214 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Exercises Program (TEP)
Number of subjects: 45
Study 21640214 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 45
Study 19274409 — intervention group
Group type: EXPERIMENTAL
Intervention: World Vision Disposable Asférica Wave Front
Number of subjects: 40
Study 19274409 — intervention group
Group type: COMPARATOR
Intervention: Acuvue 2
Number of subjects: 40
Study 19274409 — intervention group
Group type: EXPERIMENTAL
Intervention: Both soft contact lenses
Number of subjects: 40
Study 16584949 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-on therapy including heat, massage, and active exercises
Number of subjects: 24
Study 16584949 — intervention group
Group type: COMPARATOR
Intervention: Education with active exercises
Number of subjects: 24
Study 15541838 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemic preconditioning during coronary angioplasty
Number of subjects: 36
Study 15541838 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemic preconditioning
Number of subjects: 36
Study 11382647 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily disposable contact lenses
Number of subjects: 50
Study 11382647 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable extended wear contact lenses
Number of subjects: 50
Study 11382647 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 50
Study 9238873 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilized stannous fluoride dentifrice (Crest Plus Gum Care)
Number of subjects: 0
Study 9238873 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride dentifrice (Mentadent) and essential oil mouthrinse (Listerine)
Number of subjects: 0
Study 9238873 — intervention group
Group type: COMPARATOR
Intervention: Baking soda and peroxide (NaF) dentifrice (Mentadent)
Number of subjects: 0
Study 9238873 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil mouthrinse (Listerine) and stabilized stannous fluoride dentifrice (Crest Plus Gum Care)
Number of subjects: 0
Study 7952800 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone administered as a slow release formulation at 2 x 225 mg
Number of subjects: 86
Study 7952800 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone administered as a slow release formulation at 2 x 325 mg
Number of subjects: 86
Study 7952800 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone administered as a slow release formulation at 2 x 425 mg
Number of subjects: 86
Study 3306493 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g of elemental calcium per day
Number of subjects: 52
Study 3306493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 29017908 — intervention group
Group type: EXPERIMENTAL
Intervention: RD 7 bananas (more ripened, visually suboptimal)
Number of subjects: 233
Study 29017908 — intervention group
Group type: COMPARATOR
Intervention: RD 5 bananas (control)
Number of subjects: 233
Study 25637395 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat muffins
Number of subjects: 12
Study 25637395 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice muffins
Number of subjects: 12
Study 25637395 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn muffins
Number of subjects: 12
Study 25637395 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat muffins
Number of subjects: 12
Study 25637395 — intervention group
Group type: EXPERIMENTAL
Intervention: Barley muffins
Number of subjects: 12
Study 25637395 — intervention group
Group type: EXPERIMENTAL
Intervention: Wholegrain muffins (excluding corn)
Number of subjects: 12
Study 25637395 — intervention group
Group type: COMPARATOR
Intervention: Reference glucose solution
Number of subjects: 12
Study 23734572 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupatadine 20 mg daily for 4 weeks
Number of subjects: 30
Study 23734572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 20142447 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin monotherapy
Number of subjects: 4491
Study 20142447 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin plus glycoprotein IIb/IIIa inhibitors
Number of subjects: 4491
Study 20142447 — intervention group
Group type: COMPARATOR
Intervention: Heparin plus glycoprotein IIb/IIIa inhibitors
Number of subjects: 4491
Study 18982784 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous interscalene block (CIB) - 7 mL/h infusion of bupivacaine 0.0625% plus 1 microg/mL of sufentanil
Number of subjects: 47
Study 18982784 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular analgesia (IA) - 25 mL of ropivacaine 0.2% plus 2 mg of morphine
Number of subjects: 47
Study 16322642 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol (n=12)
Number of subjects: 55
Study 16322642 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol and ICS (n=8)
Number of subjects: 55
Study 14614415 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week activation frequency
Number of subjects: 51
Study 14614415 — intervention group
Group type: COMPARATOR
Intervention: 1-week activation frequency
Number of subjects: 51
Study 14614415 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft plastic appliance
Number of subjects: 51
Study 14614415 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard plastic appliance
Number of subjects: 51
Study 14614415 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with PAR scores less than 15 and no planned extractions
Number of subjects: 51
Study 14614415 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with 2 or more premolars extracted
Number of subjects: 51
Study 10783528 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management service
Number of subjects: 62
Study 10783528 — intervention group
Group type: COMPARATOR
Intervention: Conventional practice CPNS
Number of subjects: 62
Study 8832536 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-week endurance training program
Number of subjects: 47
Study 1524746 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamide peroxide bleaching gel applied for three 2-hour periods per day for 9 days
Number of subjects: 20
Study 1524746 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 teeth from each bonding agent group stored in water at 37 degrees C)
Number of subjects: 20
Study 3159546 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation A (Trigynon, triphasic OC with low doses of ethinylestradiol and levonorgestrel)
Number of subjects: 38
Study 3159546 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation B (Marvelon, monophasic OC with low doses of ethinylestradiol and desogestrel)
Number of subjects: 38
Study 3159546 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation C (Ovidol, sequential OC with higher doses of ethinylestradiol and desogestrel)
Number of subjects: 38
Study 31876451 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 40
Study 31876451 — intervention group
Group type: COMPARATOR
Intervention: Sham TENS (sTENS)
Number of subjects: 40
Study 29016741 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 20
Study 29016741 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed laser delivery
Number of subjects: 20
Study 29016741 — intervention group
Group type: COMPARATOR
Intervention: Placebo-laser
Number of subjects: 20
Study 27314959 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon beta-1a 125 mcg administered subcutaneously every 2 weeks
Number of subjects: 1512
Study 27314959 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon beta-1a 125 mcg administered subcutaneously every 4 weeks
Number of subjects: 1512
Study 27314959 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1512
Study 24794696 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 60
Study 24794696 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil
Number of subjects: 60
Study 24794696 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 22855915 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk (600 mL/d)
Number of subjects: 68
Study 22855915 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein isolate (SPI) beverage (840 mL/d; 30.1 mg total isoflavones/d)
Number of subjects: 68
Study 22855915 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole soy bean (WSB) beverage (840 mL/d; 91.4 mg total isoflavones/d)
Number of subjects: 68
Study 22855915 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk, SPI beverage, WSB beverage
Number of subjects: 68
Study 21086651 — intervention group
Group type: EXPERIMENTAL
Intervention: Emoxipine (10 mg/kg, intravenous, 10-day course)
Number of subjects: 0
Study 17925060 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed messages
Number of subjects: 322
Study 17925060 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-framed messages
Number of subjects: 322
Study 17925060 — intervention group
Group type: COMPARATOR
Intervention: Loss-framed messages
Number of subjects: 322
Study 15741723 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste
Number of subjects: 4
Study 15741723 — intervention group
Group type: COMPARATOR
Intervention: Control (fluoride-free toothpaste)
Number of subjects: 4
Study 15741723 — intervention group
Group type: COMPARATOR
Intervention: Sucrose solution
Number of subjects: 4
Study 15741723 — intervention group
Group type: COMPARATOR
Intervention: Bananas
Number of subjects: 4